Indrayani Biotech Limited announced audited standalone earnings results for the fourth quarter and year ended March 31, 2021. For the quarter, net sales/revenue from operations was INR 70.813 million against INR 143.9 million a year ago. Total loss for period was INR 29.189 million against profit of INR 2.8 million a year ago. Basic LPS was INR 0.85 against EPS of INR 0.08 million a year ago. For the year, net sales/revenue from operations was INR 210.073 million against INR 498.969 million a year ago. Total loss for period was INR 108.867 million against profit of INR 8.073 million a year ago. Basic LPS was INR 3.18 against EPS of INR 0.24 million a year ago.